2016
A Biologically Effective Dose of ≥105 Gy Is Associated With Improved Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy
Stahl J, Ross R, Harder E, Mancini B, Soulos P, Dosoretz A, Finkelstein S, Shafman T, Husain Z, Evans S, Yu J, Gross C, Decker R. A Biologically Effective Dose of ≥105 Gy Is Associated With Improved Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: s174-s175. DOI: 10.1016/j.ijrobp.2016.06.438.Peer-Reviewed Original Research
2013
Dosimetric and clinical predictors of the development of moist desquamation in breast cancer irradiation
Rutter C, Qin L, Higgins S, Moran M, Evans S. Dosimetric and clinical predictors of the development of moist desquamation in breast cancer irradiation. Journal Of Radiation Oncology 2013, 3: 147-152. DOI: 10.1007/s13566-013-0129-0.Peer-Reviewed Original ResearchMoist desquamationWhole breast radiotherapyAdjuvant whole breast radiotherapyLogistic regressionResultsTwenty-three patientsBreast cancer irradiationKaplan-Meier analysisImpact of patientLog-rank testMultivariate logistic regressionSignificant predictorsDose-volume relationshipClinical predictorsConsecutive patientsPatient factorsBreast radiotherapyGy fractionsCancer irradiationPatientsRadiotherapyBMIBreastTreatment factorsGyDesquamation